Key Takeaways
- Tirzepatide’s most common side effects are gastrointestinal — nausea (~12–30%), diarrhea (~13–24%), constipation (~6–17%), and vomiting (~6–12%), generally higher at higher doses.
- They are worst early and after dose increases, which is why the dose is raised slowly over months.
- In the head-to-head SURMOUNT-5 trial, GI effects severe enough to stop treatment were somewhat less frequent than with semaglutide.
- Serious but uncommon risks include pancreatitis, gallbladder disease, kidney injury from dehydration, and a boxed warning about thyroid C-cell tumors (seen in rodents).
- This is general education — report anything severe or persistent, and never change your dose on your own.
What tirzepatide is
Tirzepatide is a dual GIP and GLP-1 receptor agonist — it acts on two gut hormones rather than one. It is sold as Zepbound (weight management and obstructive sleep apnea) and Mounjaro (type 2 diabetes). Acting on two appetite pathways is part of why it tends to produce strong weight loss, and, like all drugs in this class, why its side effects are mostly digestive. See our full tirzepatide profile for the overview.
Common side effects, with rates
Based on the Zepbound clinical trials and prescribing information, the most common effects (with approximate reported ranges across doses) are:
- Nausea — about 12–30%. The most common effect, and worst right after starting or increasing the dose.
- Diarrhea — about 13–24%.
- Constipation — about 6–17%.
- Vomiting — about 6–12%.
- Abdominal pain, indigestion, and burping.
- Injection-site reactions, fatigue, and hair loss are also listed.
For context on tolerability: in the Zepbound weight-loss trials, discontinuation due to gastrointestinal side effects was about 3.3% at the 10 mg dose and 4.3% at 15 mg, versus about 0.5% on placebo. Most people, in other words, tolerate it well enough to continue.
Serious side effects to know
Uncommon, but worth recognizing:
- Pancreatitis. Severe, ongoing abdominal pain — often radiating to the back — needs urgent care. In the trials, confirmed acute pancreatitis was rare (about 0.2%, similar to placebo).
- Gallbladder disease. Rapid weight loss raises gallstone risk; a small number of trial participants needed gallbladder removal. Upper-right abdominal pain, fever, or jaundice warrants evaluation.
- Acute kidney injury from dehydration, usually driven by persistent vomiting or diarrhea — another reason to keep fluids up.
- Thyroid C-cell tumors (boxed warning). Seen in rodents; human risk not established. Tirzepatide is contraindicated with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.
- Hypoglycemia (mainly if combined with insulin or a sulfonylurea), allergic reactions, and diabetic retinopathy changes in people with type 2 diabetes.
How to manage the common ones
The same playbook that works for other GLP-1 drugs works here:
- Smaller, lower-fat meals, eaten slowly, stopping at the first sign of fullness.
- Avoid heavy, greasy, or very large meals, which worsen nausea on a drug that slows stomach emptying.
- Stay hydrated, and keep fluids up through any diarrhea or vomiting.
- Don’t lie down right after eating.
- Protect protein and total calories so the appetite drop doesn’t tip into under-eating and muscle loss — see Protein First.
- Slow the titration if a dose step is rough; prescribers can usually hold a dose longer rather than force the increase.
When to contact your clinician
Get prompt care for severe or persistent abdominal pain, signs of a gallbladder or pancreas problem, an allergic reaction, or dehydration from ongoing vomiting or diarrhea. If side effects make the medication hard to stay on, that is a conversation about dose and pace — and possibly about whether a different GLP-1 fits you better. Our Wegovy vs. Zepbound comparison and semaglutide side effects page cover the alternatives.
General information only — not a substitute for the prescribing information or your clinician’s guidance. See our editorial policy.